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ABSTRACT 
THE ASSOCIATION BETWEEN MEASURES OF ADIPOSITY AND 
ANOVULATION IN WOMEN WITH REGULAR MENSTRUAL CYCLES 
MAY 2011 
NICOLE ASH, B.S., RUSSELL SAGE COLLEGE 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Brian Whitcomb 
 
 Anovulation accounts for approximately 12 percent of all female infertility in the 
United States. Prior studies suggest women with high body mass index (BMI) have an 
increased risk of infertility, particularly obese women with abnormal cycle lengths. To 
date no studies have examined the relationship between measures of adiposity, including 
BMI and percent body fat measured by DXA scan (%BF), and anovulation among 
women with regular menstrual cycles assessed with biomarkers. We evaluated this 
association using data from the BioCycle study, a prospective cohort of 259 women with 
regular menstrual cycles. All measures of adiposity and covariates were collected at 
baseline. Anovulation was assessed via luteinizing hormone and progesterone levels in 
urine samples collected 16 times throughout two menstrual cycles.   
 A total of 34 women had at least one anovulatory cycle during the study. 
Unadjusted models for BMI show a significant decrease in risk comparing highest BMI 
quartile to the lowest, (OR: 0.29; 95% CI .090-.968). Once multivariable logistic 
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regression was used to adjust for age no significant associations were found in any BMI 
quartile, but point estimates did not change significantly. Similar trends were found using 
other measures of adiposity.  Results show that there is a non-significant inverse trend 
between adiposity and anovulation in healthy women with regular menstrual cycles. This 
relationship can possibly be explained by age due to the influence of time since menarche 
(TSM). Further research is needed to examine this relationship.   
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CHAPTER I 
INTRODUCTION 
 
 According to the clinical definition, infertility occurs when a couple, not using 
contraception, is unable to become pregnant after twelve or more months of trying (1). In 
2002, the National Survey of Family Growth estimated that 7.4% or 2.1 million women 
in the US are infertile (1). Infertility can be divided into four categories: female 
infertility, male infertility, female and male combined infertility, and unknown cause. It is 
estimated that somewhere between 50-60% of infertility cases are due to female 
infertility and 30-40% are due to both male and female infertility problems (2).  
 Female infertility can be further subdivided into 8 categories: hypothalamic-
pituitary factors, ovarian factors, tubal/peritoneal factors, uterine factors, cervical factors, 
vaginal factors, genetic factors, and unknown etiology. It is estimated that approximately 
12% of all female infertility can be attributed to ovarian dysfunction; either the 
inadequate formation of the corpus luteum or inability to produce an oocyte (2).  Women 
with regular menstrual cycles may have infertility and not be aware of the fact until they 
try to become pregnant because anovulatory cycles are asymptomatic.  
 Increased adiposity may contribute to anovulation through disturbances in the 
hypothalamic-pituitary-ovarian (HPO) axis, which regulates reproductive hormones. 
There is research supporting the association between obesity and the disruption in 
ovulation via two mechanisms: 1) hyperandrogenism and 2) insulin resistance (3, 4). 
 To date no epidemiologic studies have evaluated the association between 
adiposity and anovulation in a population of women with regular menstrual cycles using 
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biomarkers as a measure for anovulation. However, studies using other measures of 
infertility found an increase in risk between body mass index (BMI) and infertility (5-21). 
In addition BMI has been found to affect fertility and response to fertility treatments 
among women with reproductive disorders known to have anovulation as a symptom (22-
25). There also have been no studies that look at the association between multiple 
measures of adiposity and anovulation using a better predictor of adiposity other than 
BMI.  
 The identification of a modifiable factor such as adiposity, which can affect 
fertility in all women, would give physicians other options prior to using infertility 
treatment.  Because anovulation is not easily detected without a biomarker it is important 
that studies incorporate this measure. It is important to look at the normal menstrual cycle 
in a healthy population in an attempt to identify possible changes that are present before a 
woman needs to seek medical treatment for fertility problems. Therefore, we propose to 
assess the relationship between BMI and anovulation using data from the BioCycle 
Study, a prospective study of women who reported regular menstrual cycles and did not 
have any other medical conditions that could affect ovulation. The participants had 16 
visits during which both blood and urine were collected to measure multiple biomarkers 
of menstrual cycle status and ovulation.  
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CHAPTER II 
PHYSIOLOGY OF ADIPOSITY AND ANOVULATION 
 
 There are a several biological mechanisms through which obesity may increase 
the risk for anovulation. These mechanisms center on the HPO axis, which regulates both 
the menstrual cycle and ovulatory function through a complex hormonal regulation 
system. The two main disturbances to the HPO axis occur through either 
hyperandrogenism or insulin resistance (4). 
 Hyperandrogenism is a biological condition where there is an excess production 
or secretion of androgens, which include sex hormones (4). Adipose tissue has been 
shown to have the potential to alter the secretion of sex hormones, given its essential role 
in both androgen production and in the conversion of androgens into sex hormones (3). 
Both androgen production and conversion affects the carrier protein sex hormone-binding 
globulin (SHBG), an important hormone in the HPO axis (3, 4). Therefore, increased 
adiposity can lead to an excess of adipose tissue, and in turn a disturbance in the 
production of SHBG and other sex hormones, disrupting normal ovulatory function (3, 
4). Therefore, it is plausible that adiposity contributes to ovulatory disorder. 
 In terms of a second mechanism, insulin resistance can lead to disturbance in 
ovulatory function. The ovary is a target organ for insulin, requiring insulin to stimulate 
the production of sex hormones (3). Adipose tissue affects insulin by producing 
metabolites used in insulin secretion and metabolism. An increased amount of adipose 
tissue may lead to an increased amount of insulin secreted and altered metabolism, in turn 
causing insulin resistance throughout the body, thereby increasing the amount of 
4 
circulating insulin (4). This increased insulin level will negatively affect the ovary and its 
sex hormone production, affecting the HPO axis and altering ovarian function. Therefore, 
it is plausible that increased adiposity contributes to altered ovarian function. 
In summary, there is biological evidence supporting the hypothesis that obesity increases 
the risk for anovulation through the disruption of HPO axis by hyperandrogenism, and/or 
insulin resistance.  
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CHAPTER III 
EPIDEMIOLOGY OF ADIPOSITY AND ANOVULATION 
 
 Approximately 21 studies have examined the association between obesity and 
anovulation. Epidemiologic studies looking at BMI and anovulation measured by 
biomarkers are sparse (9, 20, 23, 24). Previous studies have examined obesity and 
fecundability, which is the probability for a woman to conceive during a given menstrual 
cycle, (5, 6, 8, 17-19), and/or measuring time to pregnancy (TTP), which is a measure of 
length of time it takes to become pregnant (7, 10-16, 21). These studies were conducted 
among women diagnosed as subfertile (5-19), or women with polycystic ovarian 
syndrome (PCOS) (22-25). To our knowledge no previous studies have looked at women 
with regular menstrual cycles using the design we are interested in investigating. 
 Studies looking at BMI and fecundability or TTP have consistently observed 
inverse associations (5-8, 14-16, 18, 21, 26). Other studies focusing on infertility, in a 
case-control setting, found that those who had increased obesity measured by BMI were 
at greater risk for infertility when compared to those who were fertile (10-13, 19). 
Finally, studies conducted among women who have PCOS, a reproductive syndrome with 
decreased ovulation as one of its main symptoms, found that there was an inverse 
association between obesity and fertility (22-25). None of these studies were conducted 
among women with regular menstrual cycles and none have measured ovulation using 
biomarkers. 
 To our knowledge no studies to date have used multiple measures of adiposity in 
an attempt to examine the amount of misclassification that can be introduced by only 
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using BMI. Previous studies have been done looking at measures other than the standard 
BMI and anovulation (27) and have found a similar increased risk of anovulation with 
increased adiposity. There have been studies that have looked at multiple measures of 
adiposity as predictors for all cause mortality (28) and cardiovascular disease (29) and 
were used to identify potential exposure variables reflecting adiposity. 
 In a large retrospective study among 10,903 Danish women who attended 
antenatal care for their first planned and successful pregnancy, Jensen et al. assessed the 
relationship between BMI and the fecundability odds ratio (FR) (5). Around the twentieth 
week of gestation, women were asked the number of months they were trying to 
conceive, if they had normal menstrual cycles, and their height and pre-pregnancy 
weight. This information was then used to calculate TTP and BMI.  After adjusting for 
potential confounders, the fecundability for an “overweight” woman (defined as a BMI 
>25 kg/m
2
) was decreased when compared to that of a “normal weight” woman (defined 
as a BMI 20-25 kg/m
2
) (FR: 0.77; 95% confidence interval (CI) 0.70-0.84). Those with a 
BMI below normal (<20 kg/m
2
) also had decreased fecundability as compared to normal 
weight woman, although this was not statistically significant (FR: 0.95; 95% CI 0.90-
1.01). 
 Due to the exclusion of non-pregnant women, those at highest risk were likely not 
included. In addition, the measure of fecundability relied on each woman’s definition of 
“trying” to become pregnant and is therefore subject to “wantedness bias” (30). This is 
not an accurate measure of true ovulatory function, which is instead more accurately 
measured through biomarkers that can assess the level of hormones and the point of 
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ovulation in a woman’s cycle. This information would tell the researcher whether each 
particular cycle was even ovulatory.  
 Rich-Edwards et al. were the first to examine the relationship between BMI and 
infertility. In a nested case-control study using data from the Nurses’ Health Study II, the 
authors defined cases as married nulliparous women who self reported inability to 
become pregnant for at least one year because of an ovulatory disorder (n=2,527). 
Controls were defined as married parous women who had no history of infertility 
(n=46,718) (11). Self reported height and weight at age 18 was used to calculate BMI for 
all study participants. After adjustment for potential confounders those in the highest 
BMI category of ≥ 32 kg/m2 were at an almost three-fold increased risk for infertility 
when compared to normal weight women (BMI category 20-21.9 kg/m
2
) (OR 2.7; 95% 
CI 2.0-3.7). Women with a BMI above 23.9 kg/m
2
 also had a statistically significant 
increase in risk. 
 Both exposure and outcome in this study could be misclassified due to data 
collection technique. The self reported value of BMI makes nondifferential 
misclassification of the exposure probable and this was not validated by the study. The 
use of self reported ovulatory infertility has its limitations but was validated via a 
secondary questionnaire and medical records. Among 40 out of 75 medical records 
collected, a 95% confirmation rate was found.  
 Finally, Al-azemi et al. conducted a prospective study of 270 women who were 
diagnosed with PCOS and seeking infertility treatment. The authors measured the 
association between BMI and ovulation after medical induction (22). Women in the 
highest BMI category (BMI ≥ 35 kg/m2) had a lower percentage of ovulation at 12 
8 
months when compared to women in the BMI category of 18-24 kg/m
2
 (38.3% vs. 91.9% 
p < 0.0001). The authors also found statistically significant differences in the 6 month 
ovulation percentages for the highest BMI category and for the BMI category of 30-34 
kg/m
2
 as compared to those in the BMI category of 18-24 kg/m
2
.  
 This study has limited generalizability because it was limited to a group of 
women with a reproductive disorder that affects ovulation. The authors of the study did 
not specify if they adjusted their findings for age. It is possible that the results they found 
are confounded if they did not adjust for this important variable. It is important to know 
the effect of BMI in healthy women because it can be used as a potential risk factor for 
ovulatory problems.   
 In summary, no previous studies have prospectively assessed the association of 
BMI and anovulation using biomarkers among a population of women with regular 
menstrual cycles. However, prior epidemiological studies have found an inverse 
association between BMI and fecundability and TTP (5-9, 12-21). Researchers have also 
looked at women diagnosed with infertility and found this association (10, 11, 22-25). 
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CHAPTER IV 
SUMMARY 
 
 Infertility is estimated to affect 7.4% of the US population and 50-60% of cases 
can be attributed to female infertility. Anovulation is an asymptomatic event that is 
difficult to measure without biological measures (1, 2). BMI may lead to ovulation 
disruption via hormonal disruptions of the HPO axis due to hyperandrogenism and 
insulin resistance (3, 4). 
 Epidemiologic evidence suggests that a positive relationship between BMI and 
decreased fecundity, increased TTP, and increased infertility (5-9, 12-21). Other studies 
limited to women with reproductive disorders also found a relationship between BMI and 
fertility (10, 11, 22-25). However, none of these studies have prospectively examined this 
association among women with regular menstrual cycles using biomarkers to assess 
ovulation.  
 Therefore, we examined the relationship between measures of adiposity and 
anovulation using biomarkers in a population of women with regular menstrual cycles 
and no history of other infertility problems. 
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CHAPTER V 
HYPOTHESIS AND SPECIFIC AIMS 
 Using a prospective cohort design, we evaluated the relationship between multiple 
measures of adiposity and anovulation among women with regular menstrual cycles. The 
following aim was addressed: 
 Specific Aim 1:  To evaluate the association between BMI and anovulation in 
 women with regular menstrual cycles. 
 Hypothesis 1: Among adult females with regular menstrual cycles, those who 
 have higher BMI will have an increased risk for anovulation as compared to 
 those with normal BMI.  
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CHAPTER VI 
METHODS 
Study Design and Population 
 Using a prospective cohort study design we evaluated the association between 
BMI and anovulation. We also evaluated other measures of adiposity as possible 
predictors of anovulation. We used data collected as part of the BioCycle Study 
conducted at University of Buffalo in Buffalo, New York between 2005 and 2007.  
 A detailed description of the study population and design has previously been 
published (26, 31-34).  Briefly, healthy, regularly menstruating premenopausal women 
were recruited from clinical practices, University of Buffalo health services, flyers, radio 
& television ads, and local newspapers. The study was designed to include a total of 16 
cycle visits over two menstrual cycles with visits usually scheduled to match key biologic 
processes in menstrual cycle function. The initial schedule was based on a normal 28 day 
cycle and had women come into the clinic on day 2, 7, 12, 13, 14, 18, 22, and 27. Fertility 
monitors were used to modify the schedule of clinic visits based on the individual 
woman’s cycle.  At these visits, blood and urine samples were obtained and in-person 
interviews were conducted. 
 Interested participants were scheduled for a screening visit where all exclusion 
factors were measured. At the end of this exclusion visit a baseline/enrollment visit was 
scheduled 1-2 weeks prior to the subjects’ next menstrual period. At this visit, physical 
and anthropometric measures were taken, blood and urine samples were obtained, and 
questionnaires were completed. The participants were given a daily diary and home 
fertility monitor to take home with them and detailed instructions were provided for use 
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of both tools. The participants were then required to call the center on the first day of 
their next period to schedule an appointment for the following day. All following visit 
days were scheduled based on an algorithm using cycle length in attempt to time visits on 
the correct days of the menstrual cycle (35). The participants began using the fertility 
monitor on day 6 of their cycle and were instructed to come in if the monitor indicated 
“peak fertility” on a day without a scheduled visit. If there was no positive indication on 
the monitor by day 14, a visit was scheduled and the subject was instructed to continue to 
monitor for 10 additional days. The fertility monitor was only used as a tool to schedule 
visits close to ovulation. The measures from the monitor were not used in this study.  A 
total of 259 women with regular menstrual cycles participated in the study.  
 The following criterion was used as exclusion from the original study: Depo-
Provera, Norplant or intrauterine device use in the past 12 months; oral contraceptive or 
other hormone supplement use in the past 3 months; planning to attempt to conceive in 
the next 3 months; actively trying to conceive in the past  6 months; pregnancy currently 
or in past 6 months; breast feeding in the last 6 months; abnormal pap smear in last 6 
months with no subsequent normal results; laparoscopy confirmed endometriosis; current 
uterine fibroids or removal in last 12 months; history of polycystic ovary disease; history 
of Chlamydia infection or positive IgG at screening; untreated gynecological infection or 
any infection in past 6 months; gynecological surgery in past year; sought treatment for 
infertility ever; history or clinical signs of gynecological problems; infectious disease 
treated by physician in past 6 months; treatment for allergies with chronic medication; 
liver or kidney disease requiring treatment in past year; younger than 18 or older than 44; 
psychiatric condition requiring medical therapy in last year; BMI <18 or >35.0 kg/m
2
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measured in clinic; plan to consume restricted diet for weight loss or medical reasons in 
next 3 months; gastrointestinal conditions associated with mal-absorption; unwilling to 
stop regular intake of vitamin or supplements; chronic use of certain medications; 
antibiotic use in past 3 months; history of chronic disease such as heart disease, diabetes 
mellitus, cancer, inflammatory disease, autoimmune, liver or kidney, thyroid disease or 
any other endocrine dysfunction; current treatment for anemia; history of alcohol abuse; 
dependency disorder or substance abuse in past 30 days; self report of regular illicit drug 
use in past 30 days; and diet high in phyto-estrogens. 
 
Exposure Assessment 
BMI was calculated using height and weight as measured by trained study personnel. The 
measures were obtained at eight points in the cycle but only height and weight at baseline 
visit was used. For our analysis, BMI was broken into quartiles. BMI was also be 
analyzed continuously to evaluate a dose-response relationship (Table 1). We evaluated 
the following measures of adiposity as possible predictors of anovulation, all of which 
were measured at baseline: waist to hip ratio (WHR), percent body fat from Dual-energy 
X-ray absorptiometry (DXA) scan, percent truncal fat from DXA, truncal to leg fat from 
DXA, and total skinfold thickness.  All measures were evaluated at as quartiles and 
continuous variables (Table 1). 
 
Validity of Exposure Assessment 
 To date DXA scan is considered one of the gold standards for measuring the true 
amount of body fat a person has and the validity of the other measures of adiposity are 
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often compared to this measure (36).  The assessment of whether measured BMI is a true 
measure of percent body fat has been assessed in previous studies (37). Blew et al. 
measured the reliability between BMI calculated using height and weight measured by 
the same instrument and percent body fat calculated from a DXA scan, which gives a true 
measure of body fat. They found that among their population of women ages 40-66 there 
was a high correlation between BMI and %body fat (r=0.81).  Sensitivity for BMI was 
25.6% and specificity was 99.3% using the NIH definition of obesity at 30 kg/m
2
 (37).  
Taylor et al. measured the reliability between WHR and truncal fat measured by DXA 
and found that among children 3-19 years old there was a correlation of value of 0.73 
(38). Durin et al. found that when using total skin fold measurements that there was a 
correlation value of 0.80 when comparing skinfold thickness to %body fat among young 
women (39).  
 
Outcome Assessment 
 Anovulation was identified using the biomarkers of LH and progesterone, 
measured in urine collected at the 16 visits to the clinic during their cycle. A woman was 
classified as anovulatory if peak progesterone concentration across the cycle was ≤ 
5ng/ML, reflective of corpus luteum failure, and there was no LH peak, reflective of 
failure of oocyte being released, measured during at least one menstrual cycle. This 
criterion was previously used in other studies using these data (26). The variable was 
dichotomized into a “yes/no” variable (Table 1). 
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Validity of Outcome Assessment 
 The validity of using LH urinary levels as a marker for ovulation has been shown 
to have high validity. Guida et al. found that among 40 women ages 21-42 there was 
100% correlation between urinary LH measured daily and ultrasound diagnosis of 
ovulation with no difference in the accuracy and precision of LH and ultrasound (p < 
0.05) (40). For this study, interassay coefficients of variation of LH were less than 4% 
and for progesterone 14% (41, 42).  
 
Covariate Assessment 
 Data for all covariates were collected via self report during in-person interviews 
during the study (Table 1). We used baseline/enrollment measures of age; history of 
smoking;  history of alcohol use; stress using Cohen’s Perceived Stress Scale, a scale that 
is used to measure participants perception of stress with high validity and reliability (43); 
race; education; use of oral contraceptives; prior pregnancy; time since menarche (TSM) 
and physical activity measured by the International Physical Activity Questionnaire 
(IPAQ) score, a tool to quantify physical activity that has been shown to have high 
validity (44). These factors have been found to be important covariates in prior studies of 
fertility (5, 6, 9-11, 45). 
 
Data Analysis Plan 
Specific Aim: To evaluate the association between BMI and anovulation. 
Univariate Analysis 
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We calculated number and percentages of women in relation to the population 
characteristics as well as their BMI categories and anovulation status (Table 1). 
Bivariate Analysis 
Covariates were cross tabulated with BMI quartiles (Table 2b) and with anovulation 
status (Table 3) to evaluate potential confounders. Chi-square tests were used when cell 
size is sufficient to assess homogeneity in the distribution. If the cell size was not 
sufficient, Fishers exact test was used instead. P-values were derived from the Chi-square 
tests for categorical variables and 2 sample t-tests for continuous variables.  
Multivariable Analysis 
Logistic regression was used to provide an unadjusted odds ratio and 95% confidence 
interval for the association between BMI and anovulation (Table 4).  Multivariable 
logistic regression was then be used to model the relationship between BMI and 
anovulation adjusting for potential confounders (Table 4). Covariates which change the 
estimates for BMI by 10% or greater when added to the model were considered 
confounders and retained in the multivariable model.  Continuous variables were tested 
for linearity in the logit and included as a continuous variable only if they met this 
criterion. Generalized estimating equations (GEE) were used to examine the same 
relationship by cycle instead of woman (Table 9).  These models address the correlation 
due to the multiple cycles per women. Sensitivity analysis was done to select an age 
where the changes in the association between BMI and anovulation could be explained. 
We stratified the data based on age, (Table 7). We also examined detailed information on 
specific covariates based on the stratification groups (Table 5 & 6). 
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 Finally we examined other measures of adiposity to see if the association found 
between BMI and anovulation was the same among all other measures. We first 
examined the correlation between all measures of adiposity (Table 2a). We then chose 
percent body fat (%BF) from DXA scan, which is a golden standard, to look at  bivariate 
relationships between %BF and covariates (Table 2c). Finally we looked at the 
unadjusted and adjusted models of each measure of adiposity (Table 4). 
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CHAPTER VII 
SIGNIFICANCE 
 
 To date no studies have evaluated the association between adiposity and 
anovulation in women with regular menstrual cycles. These women are an important 
population to examine because if there is a difference in their risk for anovulation than 
they can be identified prior to seeking medical help for fertility problems. Given that 
adiposity is potentially modifiable risk factor for women who are having trouble 
conceiving, research to evaluate this relationship is pertinent. Results from this study will 
further research in this area and may suggest a way to increase conception potential 
among women with regular menstrual cycles. 
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CHAPTER VIII 
HUMAN SUBJECT PROTECTION 
 
 The BioCycle study was approved by the Institutional Review Boards of 
University of Buffalo, the National Institutes of Health, and University of Massachusetts. 
All participants were required to sign an informed consent statement indicating that they 
understood the study requirements, that they were under no obligation to participate, and 
that they could withdraw at any time.  
 Every effort is made to ensure that confidential information remains secure. Study 
personnel were trained in privacy protocols and all study records are kept under lock and 
key at the original study site. Computer files are kept on a secure server that is password 
protected, with only study personnel able to get access to these files once permission is 
granted from the study coordinator.  
 The known risk to participants is adverse reactions to blood draws during the 
study visit, which all participants were informed of before signing the consent. There is 
also a possibility that potentially sensitive information about the participants could be 
obtained if there were to be a confidentiality breach. Given that all study personnel are 
trained in privacy procedures, this is unlikely to occur. The only known benefit to the 
participants in the study was the knowledge that they would be advancing science in the 
area of women’s reproductive health. 
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CHAPTER IX 
PERMISSION TO ACCESS DATA 
  
 I, Nicole Ash received permission to use the BioCycle Study database from Brian 
W. Whitcomb, BioCycle Study investigator. The BioCycle Study was approved by IRBs 
at the University at Buffalo and the National Institutes of Health. Use of the BioCycle 
Study database for research at UMass was approved by the School of Public Health and 
Health Sciences IRB. 
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CHAPTER X 
RESULTS 
 
 Study population characteristics can be seen in Table 1. Women in the study were 
more likely to be white, non-smokers who had at least a college education, were past 
users of oral contraceptives and nulliparous. The average age of the population was 27.29 
(SD ±8.2) years with an average BMI of 24.08kg/m
2
 (SD ±3.9).  
 Table 2a shows the correlation between each of the measures of adiposity using 
Pearson’s product-moment correlation calculation. Each of the correlations was 
statistically significant, with all measures being highly correlated except for WHR.  
 Distribution of participants by BMI Quartile and %BF quartile can be seen in 
Table 2b and Table 2c respectively. The only covariate to differ significantly between the 
quartiles of BMI was age (p=0.04). The same was true for %BF.  
 Table 3 shows the distribution of participants by anovulatory status. A total of 34 
women or 13% had at least one anovulatory cycle.  There was a significant difference in 
age between the ovulatory women versus the anovulatory women. Ovulatory women had 
an average age 28.28 (SD ±8.3) years verses the anovulatory 20.79 (SD ±2.9) 
(p=<0.001). Anovulatory women also differed significantly from ovulatory women in 
regards to education level, with 20.6% of anovulatory women being college graduates 
compared to 52% of ovulatory women (p=<0.001). Previous pregnancy also differed 
between the two groups with 43.4% of ovulatory women having a previous pregnancy 
compared with 14.3% of anovulatory (p=0.04). Finally, past oral contraceptive also 
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differed between the two groups. 57.4% of the ovulatory women had used oral 
contraceptives in the past compared with 37.5% of the anovulatory women (p=0.03). 
 In unadjusted analysis, BMI quartiles 2 and 3, along with the continuous measure 
of BMI, were not significantly associated with anovulation (Table 4). Women in BMI 
quartile 2 had a non-significant 29% decreased risk for anovulation compared with 
women in BMI quartile 1 (95% CI: .28-1.82). The odds ratio comparing BMI quartile 3 
to BMI quartile 1 was the same. When BMI quartile 4 was compared to BMI quartile 1, 
women in quartile 4 had a significant 71% decreased risk for anovulation (95% CI: .090-
0.986).  Looking at BMI as a continuous variable the unadjusted odds ratio (OR) was 
0.91 (95% CI: 0.82-1.01) for each one unit increase in BMI. Once adjusted for age, the 
OR for women in the second BMI quartile compared to the first was 0.66 (95% CI: 0.24-
1.80), while the OR for women in the third quartile compared to the first was 0.73 (95% 
CI: 0.26-2.01). The OR for the fourth quartile compared to the first became non-
significant 0.38 (95% CI: .106-1.33). We also looked at BMI quintiles and sextiles and 
found similar non-significant inverse trend (Table 8). The analysis using GEE examining 
cycles instead of women found the same non-significant trend (Table 9). We found 
similar results among all measures of adiposity with no significant relationships (Table 
4). 
 We were interested in the impact age had on the BMI-anovulation relationship. 
Sensitivity analyses were done, and age of 22 years was identified as the point where 
those above and below had differenced in both their BMI and anovulation status. We 
stratified the women into those less than 22 years of age (Table 5) and greater than or 
equal to 22 years (Table 6).  This showed that women less than 22 who were anovulatory 
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were more likely to be in BMI quartile 1 and have a less time since menarche (TSM).  An 
unadjusted model of just TSM and anovulation found a significant 31% decrease in risk 
of anovulation for every year since menarche (95% CI: 0.51-0.94). Women who were 22 
or older and anovulatory also were more likely to be in BMI quartile 1 but had a much 
longer TSM.  TSM in this group was not significantly related to anovulation (OR 0.71; 
95% CI: 0.50-1.00).  When the multivariable models were examined separating the 
women into these two groups the non-significant trend was still seen but was more 
pronounced in those less than 22 years (Table 7).  
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CHAPTER XI 
DISCUSSION 
 
 In this study of 259 healthy women with regular menstrual cycles, we found no 
significant associations between adiposity and anovulation, but did find a non-significant 
inverse trend in the data. We found that women who were younger than 22 years were the 
ones who had the most cases of anovulation. These women were also found 
predominately in the first BMI quartile and to have the shortest time since menarche.   
 Our non-significant results of BMI and anovulation, among women with regular 
menstrual cycles, is different than previous findings for fecundability and TTP (5-9, 12, 
12-21) and women with diagnosed infertility (10, 11, 22-25).  We hypothesized that we 
would see the same relationship in this population of healthy women with regular 
menstrual cycles as other studies found. However, we found no significant association 
between adiposity and anovulation in this population even after adjusting for age. We did 
have a small sample size, limiting power for the study. We had 80% power to detect an 
odds ratio of 3.25 so it is possible that if we had a larger sample size we may have been 
able to detect a smaller difference in the groups.  
 Based on the findings it could be hypothesized that among young healthy women 
anovulation is strongly associated with age and time since menarche and is minimally 
influenced by adiposity. Among women ≥ 22 years there were very few anovulatory 
cycles limiting our ability to evaluate the association with BMI.  
 The range of BMI in our study was also limited by the exclusion criteria. We had 
no individuals that were over 35 kg/m
2
, which excluded those in the higher BMI ranges 
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and could have also excluded those who would be most likely to be at risk for 
anovulation. Some of the previous studies found a U-shape association with BMI and it is 
possible that since we don’t have those in the largest BMI categories we could only be 
seeing part of this U-shape design and if we include women in with higher BMI’s then 
we may have found this U-shape in our results also. 
 Further research would need to be done to examine these two hypotheses. A study 
which included a wider range of BMI, along with increased numbers of women, could be 
beneficial to look closer at this relationship and have the statistical power to detect small 
differences that may be present. 
 It is possible that our results were affected by bias. Nondifferential 
misclassification of exposure may arise if women were to report their own height and 
weight used to calculate BMI. This type of misclassification, would underestimate any 
association seen between body mass index (BMI) and anovulation. Because we used 
trained study personnel to measured the participant’s height and weight at baseline, using 
the same equipment for everyone, the likelihood that misclassification would occur is 
minimal.   
 Nondifferential misclassification of the outcome could occur if we inaccurately 
identify a woman with ovulation as anovulatory regardless of their BMI.  If this did occur 
it would underestimate our results. Cases of anovulation are identified from lab values 
obtained during the study period. The laboratory coefficient of variance, a measure of 
reliability, for both LH and progesterone was small therefore reducing this concern (41, 
41, 42, 42). We also are using two measures to confirm the presence of anovulation, both 
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low progesterone levels and missing or late LH elevations. Therefore we feel that there is 
little chance for misclassification to occur.  
 Due to the methodology of a prospective study there is little chance for selection 
bias to occur, because the exposure of BMI is measured before the outcome of an 
anovulatory cycle has happened. There is a chance for loss to follow-up to introduce bias 
into a prospective study. This can occur if women lost to follow-up were more likely to 
be in the high BMI group and also more likely to be anovulatory. If this were to happen it 
would cause an underestimation of the true relative risk. Because of the asymptomatic 
nature of anovulation we believe that the 17 participants who dropped out of the study 
before one cycle was completed did not systematically differ by exposure or outcome and 
that, therefore selection bias was unlikely to occur. 
 Prospective studies can face information bias when the diseased group of the 
study is measured more carefully for exposure, or when the exposed group is questioned 
differently than the unexposed for outcome information. An example of this is if those 
with anovulation had more study visits measuring BMI than those ovulatory cycles or if 
the samples provided by those with high BMI were checked more carefully for 
anovulation. If this did happen we may find more cases of anovulation among those in 
the high BMI category and this would bias our results by away from the null. Laboratory 
workers were blinded to the participant’s exposure information making it very unlikely 
that information bias would be present in our study.   
 We chose covariates to analyze for confounding based on their presence in 
previous literature and their effects on statistical models. We are not aware of any key 
confounding factors that were not measured during the study process. It is possible that 
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there could be some residual confounding if key factors were not measured accurately. 
An example of this would be looking at physical activity as a confounder. In our study 
this measure was based on self report and if this was not reported accurately, even after 
we adjust for it there would still be some confounding effect in the results. Because 
physical activity is inversely associated with BMI and positively associated with 
anovulation, failure to control this completely would result in an underestimation of the 
true relative risk. We believe that any residual confounding would not affect our results 
significantly.  
 Our study was limited to women with regular menstrual cycle length and we 
believe that the results of our study may be generalized to all women with normal 
menstrual cycle length. This is true because the biological mechanism through which 
BMI impacts anovulation may differ among women with abnormal menstrual cycles. 
 In conclusion, we found no significant relationship between BMI and anovulation 
among women with regular menstrual cycles. It is possible that some biases may have 
occurred in this study but we feel that they are minimal and any that do occur would bias 
our results towards the null and would underestimate the true association. The 
relationship between BMI and anovulation among women with regular menstrual cycles 
still remains unclear and there is need for further research. Studies with larger 
populations that are not so restrictive to the exposure of BMI  may have different results, 
and should be conducted before concluding that BMI has no true association with 
anovulation among women with regular menstrual cycles. 
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TABLES 
Overall
N=259
Demographics
Age (years): mean ± SD 27.29 ± 8.2
Current Smoker: n(%)
     No 200 (78.7)
     Yes 54 (21.3)
     Missing 5
Current Alcohol use: n(%)
     No 85 (33.0)
     Yes 172 (66.9)
     Missing 2
Perceived Stress Score: n(%)
     Q1(7-18) 78 (30.2)
     Q2(19-22) 64 (24.8)
     Q3(23-25) 55 (21.3)
     Q4(26-40) 61 (23.6)
     Missing 1
Race: n(%)
     White 154 (59.5)
     Black 51 (19.7)
     Other 54 (20.9)
Education Level: n(%)
     High School Graduate or Less 33 (12.7)
     Some College 101 (39)
     College Graduate and Above 125 (48.3)
Physical Activity: n(%)
     Low 25 (9.7)
     Moderate 92 (35.5)
     High  142 (54.8)
Previous Pregnancy: n(%)
     No 111 (58.7)
     Yes 78 (41.3)
Missing 70
Past OC use: n(%)
     No 115 (45.1)
     Yes 140 (54.9)
     Missing 4
Measures of adiposity
BMI,  (kg/m2): mean ± SD 24.08 ± 3.9
BMI, (kg/m2) Quartiles: n(%)
     Q1 (16.4-21.0) 65 (25.1)
     Q2 (21.1-23.5) 65 (25.1)
     Q3 (23.6-26.2) 65 (25.1)
     Q4 (26.3-35.0) 64 (24.7)
Waist to hip ratio (cm): mean ± SD 0.75 ± 0.06
% Body Fat: mean ± SD 29.54 ± 5.99
% Truncal Fat: mean ± SD 25.11 ± 7.39
Truncal/Leg Fat: mean ± SD 0.71 ± 0.15
Total skinfold thickness (mm): mean ± SD 81.18 ± 22.14
Measures of Anovulation
Anovulation: n(%)
     No 225 (86.9)
     Yes 34 (13.1)
Table 1. Population Characteristics; BioCycle Study 2005-2007.
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BMI BMI Quartile % Body Fat
% Truncal 
Fat
Waist to Hip 
Ratio
Truncal/Leg 
Fat
Total 
Skinfold 
Thickness
Total Skinfold Thickness 0.75 0.69 0.75 0.77 0.3 0.6 1
Truncal/Leg Fat 0.66 0.66 0.62 0.84 0.49 1
Waist to Hip Ratio 0.33 0.34 0.22 0.35 1
% Truncal Fat 0.79 0.75 0.95 1
% Body Fat 0.75 0.7 1
BMI Quartile 0.92 1
BMI  1
*All p values were <.0001
Table 2a. Correlation coefficients between measures of adiposity; BioCycle Study 2005-2007*.
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BMI Q1                  
(16.1-21.0)
BMI Q2       
(21.0-23.5)
BMI Q3        
(23.6-26.2)
BMI Q4             
(26.3-35.0) P Value
1
Demographics
Age: mean ± SD 25.9 ± 7.3 26.2 ± 8.00 27.5 ± 8.6 29.6 ± 8.7 0.04
Current Smoker: n(%) 0.57
     No 54 (84.4) 50 (79.4) 48 (76.2) 48 (75.0)
     Yes 10 (15.6) 13 (20.6) 15 (23.8) 16 (25.0)
     Missing (5)
Current Alcohol use: n(%) 0.85
     No 24 (36.9) 22 (33.9) 19 (30.2) 20 (31.3)
     Yes 41 (63.1) 43 (66.1) 44 (69.8) 44 (68.8)
     Missing (2)
Perceived Stress Score: n(%) 0.98
     Q1(7-18) 22 (33.9) 19 (29.7) 18 (27.7) 19 (29.7)
     Q2(19-22) 16 (24.6) 16 (25.0) 19 (29.2) 13 (20.3)
     Q3(23-25) 11 (16.9) 14 (21.9) 14 (21.5) 16 (25.0)
     Q4(26-40) 16 (24.6) 15 (23.4) 14 (21.5) 16 (25.0)
     Missing (1)
Race: n(%) 0.25
     White 36 (55.4) 43 (66.2) 37 (56.9) 38 (59.4)
     Black 12 (18.46) 7 (10.8) 15 (23.1) 17 (26.6)
     Other 17 (26.15) 15 (23.1) 13 (20.0) 9 (14.1)
Education Level: n(%) 0.35
     High School Graduate or Less 8 (12.3) 7 (10.8) 6 (9.2) 12 (18.8)
     Some College 21 (32.3) 28 (43.1) 31 (47.7) 21 (32.8)
     College Graduate and Above 36 (55.4) 30 (46.2) 28 (43.1) 31 (48.4)
Physical Activity: n(%) 0.84
     Low 8 (12.3) 4 (6.2) 8 (12.3) 5 (7.8)
     Moderate 24 (36.9) 24 (36.9) 23 (35.4) 21 (32.8)
     High  33 (50.8) 37 (56.9) 34 (52.3) 38 (59.4)
Previous Pregnancy: n(%) 0.33
     No 27 (64.3) 30 (63.8) 30 (60.0) 24 (48.0)
     Yes 15 (35.7) 17 (36.2) 20 (40.0) 26 (52.0)
     Missing (70)
Past OC use: n(%) 0.72
     No 31 (50.8) 29 (44.6) 29 (44.6) 26 (40.6)
     Yes 30 (49.2) 36 (55.4) 36 (55.4) 38 (59.4)
     Missing (4)
Measures of adiposity
Waist to hip ratio (cm): mean ± SD 0.78 ± 0.04 0.74 ± 0.05 0.77 ± 0.07 0.77 ± 0.05 <.0001
% Body Fat: mean ± SD 24.9 ± 4.0 26.3± 4.5 31.5 ± 3.8 35.6 ± 4.5 <.0001
% Truncal Fat: mean ± SD 18.9 ± 4.5 21.0 ± 4.9 27.5 ± 4.9 33.0 ± 5.1 <.0001
Truncal/Leg Fat: mean ± SD 0.59 ± 0.10 0.64± 0.10 0.76 ± 0.13 0.85± 0.12 <.0001
Total skinfold thickness (mm): mean ± SD 63.2 ± 12.8 72.3 ± 14.2 86.1 ± 13.4 104.6 ± 21.9 <.0001
Measures of Anovulation
Anovulation: n(%) 0.23
     No 53 (81.5) 56 (86.2) 56 (86.2) 60 (93.8)
     Yes 12 (18.5) 9 (13.9) 9 (13.9) 4 (6.3)
Table 2b.  Distribution of covariates according to BMI kg/m
2
 quartiles; BioCycle Study 2005-2007.
1
P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests for Continuous variables    
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% Body Fat Q1             
(15.10-24.65)
% Body Fat Q2 
(24.66-29.81)
% Body Fat Q3 
(29.82-33.53)
% Body Fat Q4       
(33.54-45.25) P Value
1
Demographics
Age: mean ± SD 26.4 ± 7.7 25.8 ± 7.8 27.5 ± 8.9 30.1 ± 8.0 0.02
Current Smoker: n(%) 0.83
     No 46 (75.4) 49 (80.3) 47 (78.3) 50 (82.0)
     Yes 15 (24.6) 12 (19.7) 13 (21.7) 11 (18.0)
     Missing (16)
Current Alcohol use: n(%) 0.57
     No 17 (27.4) 20 (32.3) 23 (37.7) 23 (37.7)
     Yes 45 (72.6) 42 (67.7) 38 (62.3) 38 (62.3)
     Missing (13)
Perceived Stress Score: n(%) 0.36
     Q1(7-18) 16 (26.2) 25 (40.3) 16 (25.8) 16 (25.8)
     Q2(19-22) 20 (32.8) 11 (17.7) 16 (25.8) 15 (24.2)
     Q3(23-25) 10 (16.4) 15 (24.2) 12 (19.4) 17 (27.4)
     Q4(26-40) 15 (24.6) 11 (17.7) 18 (29.0) 14 (22.6)
     Missing (12)
Race: n(%) 0.79
     White 38 (61.3) 39 (62.9) 35 (56.5) 35 (56.5)
     Black 14 (22.6) 10 (16.1) 11 (17.7) 15 (24.2)
     Other 10 (16.1) 13 (21.0) 16 (25.8) 12 (19.4)
     Missing (11)
Education Level: n(%) 0.33
     High School Graduate or Less 7 (11.3) 6 (9.7) 6 (9.7) 13 (21.0)
     Some College 23 (37.1) 28 (45.2) 26 (41.9) 18 (29.0)
     College Graduate and Above 32 (51.6) 28 (45.2) 30 (48.4) 31 (50.0)
     Missing (11)
Physical Activity: n(%) 0.6
     Low 4 (6.5) 8 (12.9) 3 (4.8) 7 (11.3)
     Moderate 20 (32.3) 21 (33.9) 25 (40.3) 24 (38.7)
     High  38 (61.3) 33 (53.2) 34 (54.8) 31 (50.0)
     Missing (11)
Previous Pregnancy: n(%) 0.06
     No 27 (58.7) 32 (72.7) 25 (56.8) 21 (44.7)
     Yes 19 (41.3) 12 (27.3) 19 (43.2) 26 (55.3)
     Missing (78)
Past OC use: n(%) 0.39
     No 27 (44.3) 32 (52.5) 29 (46.8) 23 (37.1)
     Yes 34 (55.7) 29 (47.5) 33 (53.2) 39 (62.9)
     Missing (13)
Measures of adiposity
BMI,  (kg/m
2
): mean ± SD 21.14 ± 1.75 22.11 ± 2.57 24.89 ± 2.75 28.25 ± 3.65 <.0001
BMI, (kg/m
2
) Quartiles: n(%) <.0001
     Q1 (16.1-21.0) 30 (48.4) 27 (43.6) 5 (8.1) 1 (1.6)
     Q2 (21.0-23.5) 27 (43.6) 19 (30.7) 13 (21.0) 3 (4.8)
     Q3 (23.6-26.2) 5 (8.1) 10 (16.1) 26 (41.9) 19 (30.7)
     Q4 (26.3-35.0) 0 (0.0) 6 (9.7) 18 (29.0) 39 (62.9)
     Missing (11)
Waist to hip ratio (cm): mean ± SD 0.74 ± 0.04 0.74 ± 0.04 0.76± 0.06 0.77 ± 0.07 0.0006
% Truncal Fat: mean ± SD 16.3 ± 2.6 22.1 ± 2.7 27.8 ± 3.1 34.2 ± 4.1 <.0001
Truncal/Leg Fat: mean ± SD 0.58 ± 0.09 0.66 ± 0.13 0.77 ± 0.13 0.83 ± 0.12 <.0001
Total skinfold thickness (mm): mean ± SD 60.9 ± 11.2 77.9 ± 15.0 84.5 ± 14.7 103.9 ± 22.5 <.0001
Measures of Anovulation
Anovulation: n(%) 0.22
     No 54 (87.1) 52 (83.9) 56 (90.3) 59 (95.2)
     Yes 8 (12.9) 10 (16.1) 6 (9.7) 3 (4.8)
     Missing (11)
Table 2c.  Distribution of covariates according to % Body fat by DXA scan quartiles; BioCycle Study 2005-2007.
1
P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests for Continuous variables    
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Ovulatory Anovulatory P-Value
1
Demographics N=225 N=34
b
Age: mean ± SD 28.3 ± 8.3 20.8 ± 2.9 < 0.001
Current Smoker: n(%) 0.92
     No 173 (78.6) 27 (79.4)
     Yes 47 (21.4) 7 (20.6)
     Missing 5 0
Current Alcohol use: n(%) 0.78
     No 73 (32.7) 12 (35.3)
     Yes 150 (67.3) 22 (64.7)
     Missing 2 0
Perceived Stress Score: n(%) 0.80
     Q1(7-18) 67 (29.9) 11 (32.4)
     Q2(19-22) 54 (24.1) 10 (29.4)
     Q3(23-25) 48 (21.4) 7 (20.6)
     Q4(26-40) 55 (24.6) 6 (17.7)
     Missing 1 0
Race: n(%) 0.70
     White 136 (60.4) 18 (52.9)
     Black 43 (19.11) 8 (23.5)
     Other 46 (20.4) 8 (23.5)
Education Level: n(%) < 0.001
     High School Graduate or Less 28 (12.4) 5 (14.7)
     Some College 79 (35.1) 22 (64.7)
     College Graduate and Above 118 (52.4) 7 (20.6)
Physical Activity: n(%) 0.65
     Low 23 (10.2) 2 (5.9)
     Moderate 81 (36.0) 11 (32.4)
     High  121 (53.8) 21 (61.8)
Previous Pregnancy: n(%) 0.04
     No 99 (56.6) 12 (85.7)
     Yes 76 (43.4) 2 (14.3)
Missing 50 20
Past OC use: n(%) 0.03
     No 95 (42.6) 20 (62.5)
     Yes 128 (57.4) 12 (37.5)
     Missing
Measures of adiposity
BMI,  (kg/m
2
): mean ± SD 24.2± 3.9 25.0± 3.4 0.08
BMI, (kg/m
2
) Quartiles: n(%) 0.23
     Q1 (16.1-21.0) 53 (23.6) 12 (35.3)
     Q2 (21.0-23.5) 56 (24.9) 9(26.5)
     Q3 (23.6-26.2) 56 (24.9) 9 (26.5)
     Q4 (26.3-35.0) 60 (26.7) 4 (11.8)
Waist to hip ratio (cm): mean ± SD 0.75 ± 0.06 0.75 ± 0.04 0.57
% Body Fat: mean ± SD 29.8 ± 6.1 27.7 ± 4.8 0.08
% Truncal Fat: mean ± SD 25.4 ± 7.5 23.0 ± 6.1 0.12
Truncal/Leg Fat: mean ± SD 0.71 ± 0.15 0.69 ± 0.16 0.67
Total skinfold thickness (mm): mean ± SD 81.9 ± 23.1 76.4 ± 14.2 0.18
Table 3.  Distribution of covariates according to anovulation status; BioCycle Study 
2005-2007.
1
P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests 
for Continuous variables   
b
At least one anovulatory cycle. 24 women had 1 anovulatory cycle and 10 had 2 anovulatory 
cycles. Total of 44 anovulatory cycles out of 509 in the study.
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N % OR 95% CI OR 95% CI
BMI Quartiles
     Q1 (16.1-21.0) 12 35.3 1.00 Referent 1.00 Referent
     Q2 (21.0-23.5) 9 26.5 0.71 (.28-1.82) 0.66 (.24-1.80)
     Q3 (23.6-26.2) 9 26.5 0.71 (.28-1.82) 0.73 (.26-2.01)
     Q4 (26.3-35.0) 4 11.8 0.29 (.090-0.99) 0.38 (.106-1.33)
Continuous BMI 34 0.91 (0.82-1.01) 0.93 (0.83-1.04)
%Body Fat Quartiles
     Q1 (15.1-24.7) 8 3.23 1.00 Referent 1.00 Referent
     Q2 (24.8-29.8) 10 4.03 1.3 (.475-3.55) 1.05 (.36-3.10)
     Q3 (29.9-33.5) 6 2.42 0.72 (.235-2.22) 0.69 (.21-2.29)
     Q4 (33.6-44.3) 3 1.21 0.34 (.087-1.36) 0.54 (.13-2.32)
%Body Fat Continuous 27 0.941 (.878-1.01) 0.96 (.89-1.03)
%Truncal Fat Quartiles
     Q1 (10.6-19.0) 10 4.03 1.00 Referent 1.00 Referent
     Q2 (19.1-24.8) 6 2.42 0.56 (.189-1.64) 0.38 (.11-1.20)
     Q3 (24.9-30.9) 8 3.23 0.77 (.282-2.10) 0.83 (.28-2.49)
     Q4 (31.0-45.0) 3 1.21 0.26 (.069-1.01) 0.39 (.09-1.64)
%Truncal Fat Continuous 27 0.956 (.903-1.01) 0.97 (.91-1.04)
Truncal/Leg Fat Quartiles
     Q1 (.364-.590) 8 3.23 1.00 Referent 1.00 Referent
     Q2 (.591-.705) 5 2.02 0.592 (.182-1.92) 0.58 (.17-2.02)
     Q3 (.706-.801) 7 2.82 0.859 (.291-2.53) 0.77 (.24-2.45)
     Q4 (.802-1.14) 7 2.82 0.859 (.291-2.53) 1.34 (.41-4.41)
Truncal/Leg Fat Continuous 27 0.581 (.040-8.37) 1.14 (.06-22.17)
Waist to Hip ratio Quartiles
     Q1 (.60-.717) 6 2.34 1.00 Referent 1.00 Referent
     Q2 (.718-.746) 12 4.69 2.15 (.754-6.14) 1.75 (.58-5.22)
     Q3 (.747-.781) 9 3.52 1.5 (.501-4.49) 2.01 (.63-6.43)
     Q4 (.782-1.16) 7 2.73 1.21 (.382-3.83) 1.84 (.54-6.26)
Waist to Hip ratio Continuous 34 0.127 (<.001-136.09) 5.01 (.003-999.99)
Total Skinfold Thickness Quartiles
     Q1 (32.8-66.0) 9 3.53 1.00 Referent 1.00 Referent
     Q2 (66.1-78.0) 11 4.31 1.39 (.533-3.62) 1.19 (.43-3.29)
     Q3 (78.1-94.0) 10 3.92 1.22 (.459-3.22) 1.37 (.48-3.92)
     Q4 (94.1-156.5) 4 1.57 0.437 (.127-1.50) 0.59 (.16-2.16)
Total Skinfold Thickness Continuous 34 0.988 (.971-1.01) 0.99 (.97-1.02)
1
Multivariable model adjusted for age.  
Cases Unadjusted Multivariable
1 
Table 4. Odds ratios and 95% CI of anovulation by baseline adiposity measures; BioCycle Study 
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All Ovulatory Anovulatory
BMI
     Q1 (16.1-21.0) 22 (24.18) 14 (21.5) 8 (30.8)
     Q2 (21.0-23.5) 27 (29.67) 19 (29.2) 8 (30.8)
     Q3 (23.6-26.2) 25 (27.47) 17 (26.2) 8 (30.8)
     Q4 (26.3-35.0) 17 (18.68) 15 (23.1) 2 (7.7)
Time since menarche (TSM)
3 1 (1.11) 0 (0.00) 1 (3.4)
4 2 (2.22) 0 (0.00) 2 (7.7)
5 9 (10.00) 5 (7.8) 4 (15.4)
6 13 (14.44) 9 (14.1) 4 (30.77)
7 20 (22.22) 16 (25.0) 4 (15.4)
8 21 (23.33) 14 (21.9) 7 (26.9)
9 14 (15.56) 11 (17.2) 3 (11.5)
10 10 (11.11) 9 (14.1) 1 (3.9)
Missing 1
Age
18 9 (9.89) 5 (7.7) 4 (15.4)
19 30 (32.97) 23 (35.4) 7 (26.9)
20 34 (37.36) 23 (35.4) 11 (42.3)
21 18 (19.78) 14 (21.5) 4 (15.4)
Odds Ratio for anovulation
OR 95% CI
TSM Continuous 0.69 (.51-.94)
Unadjusted
Table 5. Characteristic of women younger than 22 years; BioCycle Study 2005-2007.
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Table 6. Characteristics of women 22 years and older; BioCycle Study 2005-2007.
All Ovulatory Anovulatory
BMI
     Q1 (16.1-21.0) 43 (25.60) 39 (24.4) 4 (50.0)
     Q2 (21.0-23.5) 38 (22.62) 37 (23.1) 1 (12.5)
     Q3 (23.6-26.2) 40 (23.81) 39 (24.4) 1 (12.5)
     Q4 (26.3-35.0) 47 (27.98) 45 (28.1) 2 (25.0)
Time since menarche (TSM)
3 0 (0.00) 0 (0.00) 0 (0.00)
4 0 (0.00) 0 (0.00) 0 (0.00)
5 0 (0.00) 0 (0.00) 0 (0.00)
6 0 (0.00) 0 (0.00) 0 (0.00)
7 0 (0.00) 0 (0.00) 0 (0.00)
8 1 (.61) 0 (0.00) 1 (16.7)
9 14 (8.48) 11 (6.9) 3 (50.0)
10 8 (4.85) 8 (5.0) 0 (0.00)
11 11 (6.67) 11 (6.9) 0 (0.00)
12 14 (8.48) 13 (8.2) 1 (16.7)
13 9 (5.45) 9 (5.7) 0 (0.00)
14 8 (4.85) 8 (5.0) 0 (0.00)
15 11 (6.67) 11 (6.9) 0 (0.00)
16 3 (1.82) 3 (1.9) 0 (0.00)
17 4 (2.42) 4 (2.5) 0 (0.00)
18 2 (1.21) 1 (0.6) 1 (16.7)
19 4 (2.42) 4 (2.5) 0 (0.00)
20 4 (2.42) 4 (2.5) 0 (0.00)
21 3 (1.82) 3 (1.9) 0 (0.00)
22 7 (4.24) 7 (4.4) 0 (0.00)
23 5 (3.03) 5 (3.1) 0 (0.00)
24 5 (3.03) 5 (3.1) 0 (0.00)
25 9 (5.45) 9 (5.7) 0 (0.00)
26 4 (2.42) 4 (2.5) 0 (0.00)
27 6 (3.64) 6 (3.8) 0 (0.00)
28 8 (4.85) 8 (5.0) 0 (0.00)
29 6 (3.64) 6 (3.8) 0 (0.00)
30 10 (6.06) 10 (6.3) 0 (0.00)
31 4 (2.42) 4 (2.5) 0 (0.00)
32 4 (2.42) 4 (2.5) 0 (0.00)
33 1 (.61) 1 (0.6) 0 (0.00)
Missing 3
Odds Ratio for anovulation
OR 95% CI
TSM Continuous 0.71 (.50-1.00)
Unadjusted
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Table 7. Age stratified results for association between BMI and anovulation; BioCycle Study 2005-2007.
OR 95% CI OR 95% CI
Where age < 22
N 91 26
BMI Quartiles
     Q1 (16.1-21.0) 1.00 Referent 1.00 Referent 8 (30.8)
     Q2 (21.0-23.5) 0.74 (.222-2.44) 0.82 (.238-2.79) 8 (30.8)
     Q3 (23.6-26.2) 0.82 (.246-2.76) 0.86 (.255-2.91) 8 (30.8)
     Q4 (26.3-35.0) 0.23 (.042-1.29) 0.23 (.048-1.40) 2 (7.7)
Continuous BMI 0.89 (.763-1.04) 0.89 (.763-1.04)
1Multivariable model adjusted for age.  
OR 95% CI OR 95% CI
Where age ≥ 22
N 168 8
BMI Quartiles
     Q1 (16.1-21.0) 1.00 Referent 1.00 Referent 4 (50.0)
     Q2 (21.0-23.5) 0.26 (.028-2.47) 0.27 (.028-2.65) 1 (12.5)
     Q3 (23.6-26.2) 0.25 (.027-2.34) 0.35 (.035-3.39) 1 (12.5)
     Q4 (26.3-35.0) 0.43 (.075-2.50) 0.79 (.126-4.91) 2 (25.0)
Continuous BMI 0.94 (.781-1.14) 0.99 (.821-1.91)
1Multivariable model adjusted for age.  
Multivariable1 
Multivariable1 
Unadjusted
Unadjusted
Anovulation 
Frequency n(%)
Anovulation 
Frequency
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Table 8. BMI distributed by quintiles and sextiles; BioCycle Study 2005-2007.
Ovulatory Anovulatory
BMI, (kg/m2) Quintiles: n(%)
Q1 (16.14-20.47) 42 (18.7) 10 (29.4)
Q2 (20.48-22.61) 44 (19.6) 8 (23.5)
Q3 (22.62-24.43) 46 (20.4) 6 (17.7)
Q4 (24.44-27.03) 46 (20.4) 6 (17.7)
Q5 (27.04-34.98) 47 (20.9) 4 (11.8)
BMI, (kg/m2) Sextiles: n(%)
Q1 (16.14-20.21) 36 (16.0) 8 (23.5)
Q2 (20.22-22.12) 34 (15.1) 9 (26.5)
Q3 (22.13-23.46) 39 (17.3) 4 (11.8)
Q4 (23.47-25.07) 38 (16.9) 5 (14.7)
Q5 (25.08-27.97) 39 (17.3) 4 (11.8)
Q6 (27.98-34.98) 39 (17.3) 4 (11.8)
OR 95% CI OR 95% CI
BMI Quintiles
Q1 (16.14-20.47) 1.00 Referent 1.00 Referent
Q2 (20.48-22.61) 0.76 (.275-2.12) 0.87 (.291-2.60)
Q3 (22.62-24.43) 0.55 (.183-1.64) 0.522 (.163-1.67)
Q4 (24.44-27.03) 0.55 (.183-1.64) 0.621 (.192-2.01)
Q5 (27.04-34.98) 0.36 (.104-1.23) 0.53 (.141-1.99)
BMI Sextiles
Q1 (16.14-20.21) 1.00 Referent 1.00 Referent
Q2 (20.22-22.12) 1.19 (.412-3.44) 1.204 (.376-3.85)
Q3 (22.13-23.46) 0.46 (.128-1.67) 0.358 (.093-1.38)
Q4 (23.47-25.07) 0.59 (.177-1.98) 0.523 (.143-1.92)
Q5 (25.08-27.97) 0.46 (.128-1.67) 0.616 (.154-2.47)
Q6 (27.98-34.98) 0.46 (.128-1.67) 0.507 (.127-2.02)
Multivariable1 Unadjusted
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OR 95% CI OR 95% CI
BMI Quartiles
     Q1 (16.1-21.0) 1.00 Referent 1.00 Referent
     Q2 (21.0-23.5) 0.67 (0.256-1.73) 0.65 (0.243-1.71)
     Q3 (23.6-26.2) 0.66 (0.254-1.70) 0.67 (0.251-1.77)
     Q4 (26.3-35.0) 0.20 (0.063-0.650) 0.26 (0.075-1.15)
Continuous BMI 0.89 (0.805-0.98) 0.90 (0.803-1.01)
%Body Fat Quartiles
     Q1 (15.1-24.7) 1.00 Referent 1.00 Referent
     Q2 (24.8-29.8) 1.69 (0.611-4.67) 1.35 (0.466-3.90)
     Q3 (29.9-33.5) 0.98 (0.251-2.49) 0.76 (0.246-2.35)
     Q4 (33.6-44.3) 0.28 (0.073-1.10) 0.44 (0.103-1.90)
%Body Fat Continuous 0.94 (0.889-0.985) 0.95 (0.895-1.01)
Unadjusted Multivariable1 
Table 9. Odds ratios and 95% CI of anovulation per cycle by 
adiposity measures: BioCycle Study 2005-2007
 
39 
REFERENCES 
1. Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and 
reproductive health of U.S. women: data from the 2002 National Survey of Family 
Growth. Vital Health Stat 23. 2005;(25)(25):1-160.  
2. Infertility: Risk Factors , Mayo Foundation for Medical Education and Research, 2010. 
(http://www.mayoclinic.com/health/infertility/DS00310/DSECTION=risk-factors).  
3. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. 
Reproduction. 2010;140(3):347-64. (doi: 10.1530/REP-09-0568).  
4. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod 
Biomed Online. 2006;12(5):542-51.  
5. Jensen TK, Scheike T, Keiding N, et al. Fecundability in relation to body mass and 
menstrual cycle patterns. Epidemiology. 1999;10(4):422-8.  
6. Yilmaz N, Kilic S, Kanat-Pektas M, et al. The relationship between obesity and 
fecundity. J Womens Health (Larchmt). 2009;18(5):633-6. (doi: 10.1089/jwh.2008.1057).  
7. van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous 
pregnancy chances in subfertile, ovulatory women. Hum Reprod. 2008;23(2):324-8. (doi: 
10.1093/humrep/dem371).  
8. Ramlau-Hansen CH, Thulstrup AM, Nohr EA, et al. Subfecundity in overweight and 
obese couples. Hum Reprod. 2007;22(6):1634-7. (doi: 10.1093/humrep/dem035).  
9. Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. 
Hum Reprod. 2007;22(2):414-20. (doi: 10.1093/humrep/del400).  
10. Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility. 
Epidemiology. 1994;5(2):247-50.  
11. Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and 
infertility caused by ovulatory disorder. Am J Obstet Gynecol. 1994;171(1):171-7.  
12. Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass 
index, and ovulatory disorder infertility. Epidemiology. 2002;13(2):184-90.  
13. Hartz AJ, Barboriak PN, Wong A, et al. The association of obesity with infertility and 
related menstural abnormalities in women. Int J Obes. 1979;3(1):57-73.  
40 
14. Killick S, Trussell J, Cleland K, et al. Factors associated with subfertility among 
women attending an antenatal clinic in Hull. Hum Fertil (Camb). 2009;12(4):191-7. (doi: 
10.3109/14647270903386807).  
15. Bolumar F, Olsen J, Rebagliato M, et al. Body mass index and delayed conception: a 
European Multicenter Study on Infertility and Subfecundity. Am J Epidemiol. 
2000;151(11):1072-9.  
16. Lake JK, Power C, Cole TJ. Women's reproductive health: the role of body mass 
index in early and adult life. Int J Obes Relat Metab Disord. 1997;21(6):432-8.  
17. Koch E, Bogado M, Araya F, et al. Impact of parity on anthropometric measures of 
obesity controlling by multiple confounders: a cross-sectional study in Chilean women. J 
Epidemiol Community Health. 2008;62(5):461-70. (doi: 10.1136/jech.2007.062240).  
18. Basso O, Olsen J, Bisanti L, et al. Repeating episodes of low fecundability. A 
multicentre European study. The European Study Group on Infertility and Subfecundity. 
Hum Reprod. 1997;12(7):1448-53.  
19. Green BB, Weiss NS, Daling JR. Risk of ovulatory infertility in relation to body 
weight. Fertil Steril. 1988;50(5):721-6.  
20. Hernandez Garcia IA, Gutierrez Gutierrez AM, Gallardo Lozano E. Effect of weight 
reduction on the clinical and hormonal condition of obese anovulatory women. Ginecol 
Obstet Mex. 1999;67:433-7.  
21. Wise LA, Rothman KJ, Mikkelsen EM, et al. An internet-based prospective study of 
body size and time-to-pregnancy. Hum Reprod. 2010;25(1):253-64. (doi: 
10.1093/humrep/dep360).  
22. Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility 
management in women with polycystic ovary syndrome. Arch Gynecol Obstet. 
2004;270(4):205-10. (doi: 10.1007/s00404-003-0537-2).  
23. Dravecka I, Lazurova I, Kraus V. Obesity is the major factor determining an insulin 
sensitivity and androgen production in women with anovulary cycles. Bratisl Lek Listy. 
2003;104(12):393-9.  
24. Hsu MI, Liou TH, Liang SJ, et al. Inappropriate gonadotropin secretion in polycystic 
ovary syndrome. Fertil Steril. 2009;91(4):1168-74. (doi: 
10.1016/j.fertnstert.2008.01.036).  
25. Holte J, Bergh T, Gennarelli G, et al. The independent effects of polycystic ovary 
syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in 
premenopausal women. Clin Endocrinol (Oxf). 1994;41(4):473-81.  
41 
26. Gaskins AJ, Mumford SL, Zhang C, et al. Effect of daily fiber intake on reproductive 
function: the BioCycle Study. Am J Clin Nutr. 2009;90(4):1061-9. (doi: 
10.3945/ajcn.2009.27990).  
27. Moran C, Hernandez E, Ruiz JE, et al. Upper body obesity and hyperinsulinemia are 
associated with anovulation. Gynecol Obstet Invest. 1999;47(1):1-5.  
28. Simpson JA, MacInnis RJ, Peeters A, et al. A comparison of adiposity measures as 
predictors of all-cause mortality: the Melbourne Collaborative Cohort Study. Obesity 
(Silver Spring). 2007;15(4):994-1003. (doi: 10.1038/oby.2007.622).  
 
29. Menke A, Muntner P, Wildman RP, et al. Measures of adiposity and cardiovascular 
disease risk factors. Obesity (Silver Spring). 2007;15(3):785-95. (doi: 
10.1038/oby.2007.593).  
30. Joffe M, Key J, Best N, et al. Studying time to pregnancy by use of a retrospective 
design. Am J Epidemiol. 2005;162(2):115-24. (doi: 10.1093/aje/kwi172).  
31. Jean Wactawski-Wendea, Enrique F. Schisterman, Kathleen M. Hovey, et al. 
BioCycle study: design of the longitudinal study of the oxidative 
stress and hormone variation during the menstrual cycle. Paediatric and Perinatal 
Epidemiology. 2008;23(2):171. (doi: 10.1111/j.1365-3016.2008.00985.x).  
32. Whitcomb BW, Bodach SD, Mumford SL, et al. Ovarian function and cigarette 
smoking. Paediatr Perinat Epidemiol. 2010;24(5):433-40. (doi: 10.1111/j.1365-
3016.2010.01131.x).  
33. Yeung EH, Zhang C, Hediger ML, et al. Racial differences in the association between 
sex hormone-binding globulin and adiposity in premenopausal women: the BioCycle 
study. Diabetes Care. 2010;33(10):2274-6. (doi: 10.2337/dc10-0670).  
34. Mumford SL, Schisterman EF, Siega-Riz AM, et al. Cholesterol, endocrine and 
metabolic disturbances in sporadic anovulatory women with regular menstruation. Hum 
Reprod. 2011;26(2):423-30. (doi: 10.1093/humrep/deq322).  
35. Howards PP, Schisterman EF, Wactawski-Wende J, et al. Timing clinic visits to 
phases of the menstrual cycle by using a fertility monitor: the BioCycle Study. Am J 
Epidemiol. 2009;169(1):105-12. (doi: 10.1093/aje/kwn287).  
36. Svendsen OL, Haarbo J, Hassager C, et al. Accuracy of measurements of body 
composition by dual-energy x-ray absorptiometry in vivo. Am J Clin Nutr. 
1993;57(5):605-8.  
42 
37. Blew RM, Sardinha LB, Milliken LA, et al. Assessing the validity of body mass 
index standards in early postmenopausal women. Obes Res. 2002;10(8):799-808. (doi: 
10.1038/oby.2002.108).  
38. Taylor RW, Jones IE, Williams SM, et al. Evaluation of waist circumference, waist-
to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured 
by dual-energy X-ray absorptiometry, in children aged 3-19 y. Am J Clin Nutr. 
2000;72(2):490-5.  
39. Durnin JV, Rahaman MM. The assessment of the amount of fat in the human body 
from measurements of skinfold thickness. 1967. Br J Nutr. 2003;89(1):147-55.  
40. Guida M, Tommaselli GA, Palomba S, et al. Efficacy of methods for determining 
ovulation in a natural family planning program. Fertil Steril. 1999;72(5):900-4.  
41. Schisterman EF, Gaskins AJ, Mumford SL, et al. Influence of endogenous 
reproductive hormones on F2-isoprostane levels in premenopausal women: the BioCycle 
Study. Am J Epidemiol. 2010;172(4):430-9. (doi: 10.1093/aje/kwq131).  
42. Yeung EH, Zhang C, Mumford SL, et al. Longitudinal Study of Insulin Resistance 
and Sex Hormones over the Menstrual Cycle: The BioCycle Study. J Clin Endocrinol 
Metab. 2010. (doi: 10.1210/jc.2010-0702).  
43. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health 
Soc Behav. 1983;24(4):385-96.  
44. Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire 
(IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006;9(6):755-
62.  
45. Liu Y, Gold EB, Lasley BL, et al. Factors affecting menstrual cycle characteristics. 
Am J Epidemiol. 2004;160(2):131-40. (doi: 10.1093/aje/kwh188).  
 
